BeOne Medicines reported strong second quarter results, with total revenue increasing 30% year-over-year to $1.7 billion, surpassing the consensus estimate of $1.61 billion. The company delivered a GAAP diluted EPS of $2.05, also beating the expected $1.59. The performance was driven by the continued growth of its flagship oncology drug, BRUKINSA, prompting the company to raise its full-year 2026 revenue and operating income guidance.

Key Highlights

  • Global sales of the blockbuster drug BRUKINSA grew 31% year-over-year to $1.2 billion, exceeding the $1.15 billion analyst estimate.
  • The company raised its full-year 2026 revenue guidance to a range of $6.6 billion to $6.8 billion, up from a prior range of $6.3 billion to $6.5 billion.
  • GAAP operating income surged 270% to $325 million from $87.9 million in the prior-year period, demonstrating significant operating leverage.
  • Free cash flow for the quarter was $435.3 million, an increase of 98% compared to the same period last year.